Automate Your Wheel Strategy on XOMA
With Tiblio's Option Bot, you can configure your own wheel strategy including XOMA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol XOMA
- Rev/Share 3.2131
- Book/Share 7.7
- PB 6.1481
- Debt/Equity 1.5819
- CurrentRatio 4.8814
- ROIC -0.0364
- MktCap 440959969.0
- FreeCF/Share -0.7773
- PFCF -47.2474
- PE -46.1348
- Debt/Assets 0.5128
- DivYield 0
- ROE -0.1192
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | XOMA | The Benchmark Company | -- | Buy | -- | $35 | April 17, 2025 |
News
XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.
Published: September 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
EMERYVILLE, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of HilleVax, Inc. (NASDAQ: HLVX) (“HilleVax”) common stock for a price per share of $1.95 in cash (the “Cash Amount”), plus one non-tradeable contingent value right (“CVR” and together with the Cash Amount, the “Offer Price”).
Read More
Wall Street Analysts Predict an 86.05% Upside in XOMA Royalty (XOMA): Here's What You Should Know
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for XOMA Royalty (XOMA) points to an 86.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Here's Why XOMA Royalty (XOMA) Is a Great 'Buy the Bottom' Stock Now
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive
After losing some value lately, a hammer chart pattern has been formed for XOMA Royalty (XOMA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Read More
How Much Upside is Left in XOMA Royalty (XOMA)? Wall Street Analysts Think 106.15%
Published: August 18, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 106.2% in XOMA Royalty (XOMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates
Published: August 13, 2025 by: Zacks Investment Research
Sentiment: Positive
XOMA Royalty (XOMA) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of a loss of $0.12 per share. This compares to a loss of $0.28 per share a year ago.
Read More
ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction
Published: July 14, 2025 by: PRNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC and BOSTON and EMERYVILLE, Calif.
Read More
XOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last?
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
XOMA Royalty (XOMA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Read More
XOMA Royalty (XOMA) Tops Q1 Earnings and Revenue Estimates
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
XOMA Royalty (XOMA) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.26 per share. This compares to loss of $0.86 per share a year ago.
Read More
XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
EMERYVILLE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will be featured speakers at the H.C. Wainwright 1st Annual Royalty Company Virtual Conference being held May 13, 2025.
Read More
XOMA Royalty Declares Quarterly Preferred Stock Dividends
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
EMERYVILLE, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and Series B Cumulative Preferred Stock:
Read More
Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Capital will fund Castle Creek's D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through topline data results Ligand invested $50 million and a syndicate of co-investors invested $25 million in return for a high-single digit royalty on D-Fi JUPITER, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has closed a royalty financing agreement with Castle Creek Biosciences, Inc. to support the Phase 3 clinical study of D-Fi (FCX-007), Castle Creek's lead candidate, in patients with dystrophic epidermolysis bullosa (DEB).
Read More
About XOMA Royalty Corp. (XOMA)
- IPO Date 1986-06-06
- Website https://www.xoma.com
- Industry Biotechnology
- CEO Owen P. Hughes Jr.
- Employees 13